argenx SE
ARGX
Jodie situation report
argenx SE's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
- ARGX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ARGX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ARGX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
VORVor Biopharma Inc.competitorMay 13, 2026 ▾
“Competition The autoimmune field is a competitive landscape involving multiple fusion protein class members (atacicept, povetacicept), monoclonal antibodies, other biologics, chimeric antigen receptor (CAR) T cells and small molecules either already marketed…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARGX is currently a Leader in the organic co-movement group Autoimmune Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ARGX; it is not active in the latest market snapshot.